|
|
Article: AstraZeneca Presents New Data for Use of ZOMIG(R) (zolmitriptan) Nasal Spray in Adolescents at the American Headache Society Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- June 23, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- ZOMIG Nasal Spray Demonstrates Relief for Adolescent Migraine in a Clinical Trial --
PHILADELPHIA, June 23 /PRNewswire-FirstCall/ -- New clinical trial data presented today at the 47th American Headache Society (AHS) Annual Scientific meeting showed that AstraZeneca's ZOMIG (zolmitriptan) Nasal Spray 5 mg achieved a 58.1 percent headache response rate in adolescents compared to 43.3 percent with placebo after one hour (p
"For so long, migraine treatment research in adolescents has been limited," said Dr. Paul Winner, co-director of the Palm Beach Headache Center. "This study is an important step in understanding adolescent response to migraine treatment."
...